on Friday that it had approved Sanofi SA and Regeneron
Pharmaceuticals Inc's Zaltrap for use in combination
with a folinic acid, fluorouracil and irinotecan chemotherapy
regimen to treat adults with colorectal cancer.
Friday, 3 August 2012
U.S. FDA approves Zaltrap for metastatic colorectal cancer
Aug 3 (Reuters) - The U.S. Food and Drug Administration said
on Friday that it had approved Sanofi SA and Regeneron
Pharmaceuticals Inc's Zaltrap for use in combination
with a folinic acid, fluorouracil and irinotecan chemotherapy
regimen to treat adults with colorectal cancer. 
on Friday that it had approved Sanofi SA and Regeneron
Pharmaceuticals Inc's Zaltrap for use in combination
with a folinic acid, fluorouracil and irinotecan chemotherapy
regimen to treat adults with colorectal cancer.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment